<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128245</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981E2205</org_study_id>
    <nct_id>NCT00128245</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca</brief_title>
  <official_title>A 24-week Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%)
      ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS,
      dry eye syndrome) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 week's treatment with 2 concentrations of pimecrolimus (0.3% and 1 %)in one sign and one symptom</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in fluorescein corneal staining and ocular discomfort(worst symptom,VAS)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 week's treatment with 2 concentrations of pimecrolimus (0.3% and 1 %)on all signs and symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy and tolerability</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment>440</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Pimecrolimus 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASM981 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pimecrolimus 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASM981 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle with carbopol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle without carbopol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <arm_group_label>Pimecrolimus 0.3%</arm_group_label>
    <arm_group_label>Pimecrolimus 1%</arm_group_label>
    <other_name>ASM981</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Vehicle with carbopol</arm_group_label>
    <arm_group_label>Vehicle without carbopol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of artificial tear use

          -  Moderate to severe signs of dry eye

          -  Moderate to severe ocular discomfort

        Exclusion Criteria:

          -  Patients with uncontrolled systemic or ocular diseases.

          -  Have any history of refractive surgery

          -  Use any topical ocular medications other than those dispensed for the study, during
             the study

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Foulks, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>August 5, 2005</study_first_submitted>
  <study_first_submitted_qc>August 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KCS</keyword>
  <keyword>dry eye</keyword>
  <keyword>pimecrolimus</keyword>
  <keyword>Keratoconjunctivitis sicca (dry eye syndrome)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

